Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease
- PMID: 10867219
- DOI: 10.1016/s0197-4580(00)00100-7
Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease
Abstract
The monoamine oxidase-B (MAO-B) inhibitor L-deprenyl (Selegiline) is effective in treating Parkinson's disease and possibly Alzheimer's disease, with a concomitant extension of life span. It has been suggested that the therapeutic efficacy of L-deprenyl may involve actions other than the inhibition of the enzyme MAO-B. This article reviews some novel actions of L-deprenyl and suggests that stimulation of nitric oxide (NO) production could be central to the action of the drug. L-Deprenyl induced rapid increases in NO production in brain tissue and cerebral blood vessels. In vitro or in vivo application of L-deprenyl produced vasodilatation. The drug also protected the vascular endothelium from the toxic effects of amyloid-beta peptide. Because NO modulates activities including cerebral blood flow and memory, and reduced NO production has been observed in AD brain, stimulation of NO production by L-deprenyl could contribute to the enhancement of cognitive function in AD. MAO-B inhibitors are unique in that they exert protective effects on both vascular and neuronal tissue and thus warrant further consideration in the treatment of vascular and neurodegenerative diseases associated with aging.
Similar articles
-
L-deprenyl: nitric oxide production and dilation of cerebral blood vessels.Neuroreport. 1998 Aug 3;9(11):2595-600. doi: 10.1097/00001756-199808030-00031. Neuroreport. 1998. PMID: 9721939
-
Neurochemical insights into monoamine oxidase inhibitors, with special reference to deprenyl (selegiline).Acta Neurol Scand Suppl. 1983;95:43-55. doi: 10.1111/j.1600-0404.1983.tb01516.x. Acta Neurol Scand Suppl. 1983. PMID: 6145282
-
Monoamine oxidase-B inhibition in Alzheimer's disease.Neurotoxicology. 2004 Jan;25(1-2):271-7. doi: 10.1016/S0161-813X(03)00106-2. Neurotoxicology. 2004. PMID: 14697902 Review.
-
R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition.Exp Neurol. 2000 Dec;166(2):458-64. doi: 10.1006/exnr.2000.7517. Exp Neurol. 2000. PMID: 11085911
-
The molecular pharmacology of L-deprenyl.Eur J Pharmacol. 1992 Jun 5;226(2):97-108. doi: 10.1016/0922-4106(92)90170-z. Eur J Pharmacol. 1992. PMID: 1639115 Review.
Cited by
-
Agomelatine, Ketamine and Vortioxetine Attenuate Energy Cell Metabolism-In Vitro Study.Int J Mol Sci. 2022 Nov 10;23(22):13824. doi: 10.3390/ijms232213824. Int J Mol Sci. 2022. PMID: 36430306 Free PMC article.
-
Ameliorative role of Atorvastatin and Pitavastatin in L-Methionine induced vascular dementia in rats.BMC Pharmacol. 2008 Aug 9;8:14. doi: 10.1186/1471-2210-8-14. BMC Pharmacol. 2008. PMID: 18691432 Free PMC article.
-
N-(furan-2-ylmethyl)-N-methylprop-2-yn-1-amine (F2MPA): A potential cognitive enhancer with MAO inhibitor properties.CNS Neurosci Ther. 2014 Jul;20(7):633-40. doi: 10.1111/cns.12284. Epub 2014 May 21. CNS Neurosci Ther. 2014. PMID: 24848125 Free PMC article.
-
Role of Monoamine Oxidase Activity in Alzheimer's Disease: An Insight into the Therapeutic Potential of Inhibitors.Molecules. 2021 Jun 18;26(12):3724. doi: 10.3390/molecules26123724. Molecules. 2021. PMID: 34207264 Free PMC article. Review.
-
Amyloidosis in Alzheimer's Disease: The Toxicity of Amyloid Beta (A β ), Mechanisms of Its Accumulation and Implications of Medicinal Plants for Therapy.Evid Based Complement Alternat Med. 2013;2013:413808. doi: 10.1155/2013/413808. Epub 2013 May 15. Evid Based Complement Alternat Med. 2013. PMID: 23762130 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
